Genmab — Marts 2026
-
looks like we may get some data on Rina-s early april -Rinatabart sesutecan (Rina-S) plus bevacizumab (BEV) for patients (pts) with recurrent ovarian cancer (OC): First disclosure from cohort D2 of the phase 1/2 RAINFOL-01 study
Monday, April 13, 2026 via https://sgo2026annualmeeting.eventscribe.net/agenda.asp?BCFO=M|P&pfp=Browse by Day&fa=&fb=&fc=&fd=&all=1 -
Genmabs anbefaling sættes op til "køb" hos Baptista https://proinvestor.com/investornyt/1424224/genmabs-anbefaling-saettes-op-til-kob-hos-baptista
-
Så er vi nede i 1500-regi
-
Next…. 2027: Breakimg: Genmab fusionerer med Novo
-
MW" Genmab (+1,3%, 1693,50) har fået indledt dækning med anbefalingen "outperform" og kursmålet 32 dollar af børshuset Wolfe Research. Der går ti amerikanske ADR-aktier på én aktie i København, og dermed svarer kursmålet til 320 dollar - eller omregnet 2075 kr. "
-
-
'From a development perspective, the partnership between Janssen Biotech and Genmab A/S to commercialize this therapy has resulted in its use by over 748,000 patients globally' https://www.pharmtech.com/view/implications-of-eu-approval-for-j-j-s-self-administered-daratumumab
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind